Treatment outcomes and mortality of 94 patients with acromegaly.
BACKGROUND
Due to new therapeutic modalities and modified therapeutic goals outcome of patients with acromegaly may change over time and differ by centre. We analysed treatment outcomes and mortality of our patients with acromegaly seen between 1971 and 2003.


METHODS
The cohort consisted of 94 patients who had been followed for 0.3-31 years (mean 10.6 years). Remission criteria were a normalized IGF-I concentration, a nadir GH level during oral glucose load of <1.0 microg/l and a random GH value of <2.5 microg/l.


RESULTS
Transsphenoidal surgery achieved remission in 80% of patients with micro-adenomas (<1 cm), 65% with meso-adenomas (> or = 1 cm to <2 cm) and 27% with macro-adenomas (> or = 2 cm). Patients with meso-adenomas operated on after 1995 tended to have a better outcome compared to those operated on before 1995 (Remission in 83% vs. 38%). Radiotherapy resulted in disease control in 22 of 47 patients (47%). Intramuscular depot formulation of octreotide (Sandostatin LAR) led to disease control in 17 of 26 patients (65%). After multimodal therapy persistent acromegalic activity remained in 18% of the patients; only one of them had an adenoma of <2 cm. The standardized mortality ratio was 1.30 (95% CI 0.52-2.67) for patients in remission and 1.38 (95% CI 0.51-3.00) for patients with persistent acromegalic activity. CONCLUSIONS. Most patients with adenomas of <2 cm can be expected to achieve remission by transsphenoidal surgery alone. Furthermore, virtually all patients with adenomas of <2 cm and more than 80% of patients with adenomas of > or = 2 cm can be expected to achieve remission by adjuvant treatment. Aggressive multimodal therapy is critical in the management of acromegaly reducing mortality risk close to that of the general population.
Trepp
R
R
Division of Endocrinology and Diabetes, University Hospital of Bern, Inselspital, Bern, Switzerland.
Stettler
C
C
Zwahlen
M
M
Seiler
R
R
Diem
P
P
Christ
E R
ER
D000172:Acromegaly / Q000209:etiology / Q000401:mortality* / Q000628:therapy*; D000236:Adenoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D015331:Cohort Studies; D004358:Drug Therapy / Q000706:statistics & numerical data / Q000639:trends; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D019635:Neurosurgical Procedures / Q000706:statistics & numerical data / Q000639:trends; D015282:Octreotide / Q000627:therapeutic use; D010902:Pituitary Gland / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D010911:Pituitary Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011878:Radiotherapy / Q000706:statistics & numerical data / Q000639:trends; D012074:Remission Induction; D012189:Retrospective Studies; D012737:Sex Factors; D015996:Survival Rate; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013006:Growth Hormone; D015282:Octreotide